Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
Six-year results from the randomized phase III ENESTnd study continued to show higher rates of early, deep and sustained molecular responses when using Tasigna (nilotinib) compared to Gleevec (imatinib mesylate) in newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
2014 was a transformative year for The Cancer Letter.
FDA expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer.
At a meeting Dec. 2, the NCI Board of Scientific Advisors approved three concepts during a joint meeting with the National Cancer Advisory Board.
The FDA Oncologic Drugs Advisory Committee will meet Jan. 7, 2015, to discuss a biologics license application for a proposed biosimilar to Amgen Inc.'s Neupogen (filgrastim).
As Congress goes into recess and Democrats relinquish their eight-year control of the Senate, advocates for biomedical research are rethinking their approaches to a political reality not observed in nearly a decade: a Republican-controlled Congress.
The Cancer Letter asked leaders of science and cancer advocacy groups to comment on the half-percent increases in federal funding for NIH and NCI in fiscal 2015, and on the prospects of science funding when Republicans take control of Congress in January.
The 113th Congress staggered through its final spending bill, approving $1.1 trillion in a massive “cromnibus” Dec. 13, keeping most of the federal government funded through September 2015, and locking in a half-percent increase for NIH and NCI in FY2015.
Gregory BontragerGregory Bontrager resigned from his position as chief operating officer and president of the American Cancer Society.
